Mixed decisions from scheduling committee

Ranitidine set to remain an S3 medicine, while TGA decides to downschedule migraine and acne treatments The Therapeutic Goods Administration (TGA) scheduling delegate has confirmed that the reflux treatment ranitidine (Zantac) will not be downscheduled, and has also knocked back a proposal for a Selective Serotonin Reuptake Inhibitors (SSRIs) class entry. However, the migraine treatment